Scientists probe why some MS treatments may lose power
NCT ID NCT06310343
Summary
This study tested a new blood test to measure antibodies that some patients develop against the multiple sclerosis drug alemtuzumab. Researchers followed 15 patients for two years to see if these antibodies were linked to side effects, changes in immune cells, or the drug's effectiveness. The goal was to gather information to help doctors better understand and manage treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barts Health NHS Trust
London, Second Floor Neurophys Dept, United Kingdom
Conditions
Explore the condition pages connected to this study.